Condition
Stereotactic Radiation
Total Trials
5
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Active Not Recruiting2
Recruiting2
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07491211Active Not Recruiting
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
NCT04899908Phase 2Active Not Recruiting
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT07017855Not ApplicableNot Yet Recruiting
Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia
NCT06702826Phase 2Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
NCT06356779Not ApplicableRecruiting
Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease
Showing all 5 trials